Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies

Phase 2Active Not RecruitingNCT05051696

Liu Zi120 enrolled

Overview

The purpose of this clinical trial is to evaluate the effectiveness and safety of oncolytic viruses H101 intra-tumor injection combined with or without radiotherapy in refractory or recurrent gynecological malignancies. And further research the mechanism of oncolytic viruses H101.

Patients with recurrent, radiation/chemotherapy-resistant gynecological cancer carry a poor prognosis. H101 is a recombinant human type-5 adenovirus (Ad5), in which the E1B and E3 gene have been deleted. Previous studies have shown that H101 has anticancer activity and safety in some solid tumors, but has little report in gynecological oncology. In this clinical trial, 60 recurrent or refractory gynecological cancer patients will be enrolled. Based on individual conditions, all eligible patients are intra-tumor injected oncolytic viruses H101 within 5 consecutive days combined with or without radiotherapy in sequential, three weeks for a cycle (1-4 cycles totally). Simultaneously, the tumor sample, peripheral blood, and urine specimen were collected on day1 and day5. Local control rate and side effects are recorded respectively.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

120

Conditions

Genital Neoplasms, Female

Interventions

H101DRUG

Intra-tumor injected oncolytic viruses H101 within 5 consecutive days,3 weeks for a cycle (1-4cycles)

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Written informed consent obtained. * Age ≥ 18 years at the time of study entry. * Histological or Cytologically diagnosed gynecological malignancies. * Failure to prior standard treatment (surgery, chemotherapy, radiotherapy); * Refractory/recurrence/metastasis gynecological cancer * At least one measurable lesion according to the RECIST1.1. * Cooperative Oncology Group-Status (ECOG Status) 0-3. * The last treatment should be over 2 weeks. Exclusion Criteria: * History or evidence of active autoimmune disease that requires systemic treatment. * Participated in other anti-tumor clinical trials within 4 weeks. * Patients who have a contraindication to similar drugs. * That failure to follow up regularly.

Locations (1)

The First Affiliated Hospital of Xi'an Jiao Tong University

Xi'an, Shaanxi, China

Outcomes

Primary Outcomes

Local Control (LC)

LC will be measured from the start date of injection until the date of progressive disease

Time frame: 3 months

Secondary Outcomes

Objective Response Rate (ORR)

ORR is the percentage of participants with presence of complete response (CR), partial response (PR). ORR assessment will be based on RECIST 1.1 criteria

Time frame: 1 year after injection

Progress free survival (PFS)

Progress free survival is defined as the time from first day of injection until the first date of either objective disease progression or death due to any cause

Time frame: 12 months

adverse events

Toxicity were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0

Time frame: At day 3, 7 and 30

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.